Eledon Pharmaceuticals, Inc.
ELDN
$3.54
-$0.16-4.32%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -10.13% | -41.00% | 2.78% | 3.75% | 24.56% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.91% | -13.01% | -7.02% | 70.55% | 65.28% |
| Operating Income | -17.91% | 13.01% | 7.02% | -70.55% | -65.28% |
| Income Before Tax | -500.85% | 76.44% | -122.68% | 75.02% | 72.51% |
| Income Tax Expenses | -- | -91.88% | -- | -- | -- |
| Earnings from Continuing Operations | -500.85% | 76.59% | -122.68% | 75.02% | 72.51% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -500.85% | 76.59% | -122.68% | 75.02% | 72.51% |
| EBIT | -17.91% | 13.01% | 7.02% | -70.55% | -65.28% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -312.37% | 83.97% | -111.82% | 90.40% | 89.33% |
| Normalized Basic EPS | -311.98% | 82.82% | -115.28% | 86.20% | 89.32% |
| EPS Diluted | -312.37% | 83.97% | 20.04% | 90.40% | 89.33% |
| Normalized Diluted EPS | -311.98% | 82.82% | -116.32% | 86.20% | 89.32% |
| Average Basic Shares Outstanding | 45.70% | 37.25% | 48.42% | 81.02% | 157.56% |
| Average Diluted Shares Outstanding | 45.70% | 37.25% | 38.99% | 81.02% | 157.56% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |